0191677 - UMG-J 20033192 RIV NL eng J - Článek v odborném periodiku
Bubeník, Jan - Vonka, V.
MHC class I status of tumours and design of immunotherapeutic strategies.
Immunology Letters. Roč. 90, 2-3 (2003), s. 177-178. ISSN 0165-2478. E-ISSN 1879-0542
Grant CEP: GA MZd NC7148; GA MZd NC3707; GA MZd NC6957; GA MZd NC7552; GA ČR GA301/01/0985; GA AV ČR IAA5052203
Výzkumný záměr: CEZ:AV0Z5052915
Klíčová slova: MHC * beta2-mikroglobulin * immunotherapeutic strategies
Kód oboru RIV: FB - Endokrinologie, diabetologie, metabolizmus, výživa
Impakt faktor: 1.710, rok: 2003

Attention should be paid to the MHC class I status of neoplasms during the design of immunotherapy protocols. For therapy of MHC class I deficient tumours, cytokines such as IFN gamma, IL-12, IL-2, GM-CSF, either exogenous or produced by gene-modified vaccines, should be considered. The therapeutic role of the induction of MHC class I expression by demethylation and acetylation agents should also be investigated.

Trvalý link: http://hdl.handle.net/11104/0087415